Digital health care platform GoodRx has announced three senior-level leadership appointments, naming Raj Beri as chief operating offer, Mark Hull as chief product officer and Vina Leite as chief people officer, according to a Monday (May 9) press release.
The publicly traded company said in its release that the executives were added “to support the company’s scaling business and accelerate innovation to bring more affordable and convenient healthcare to consumers across the country.”
According to the release, Beri is GoodRx’s first chief operating officer and comes to the company from Uber, where he was vice president of grocery and new verticals. He oversaw last-mile and non-restaurant delivery business globally.
“I’m passionate about working on audacious problems across sectors that are ripe for disruption, and GoodRx is at the center of that disruption in the healthcare industry,” Beri said.
Hull, GoodRx’s first chief product officer, comes to company from Meta and LinkedIn, where he was a senior product executive.
“Mark will draw on his more than 25 years of experience in the product management industry to make GoodRx more accessible, convenient and useful for consumers, while helping scale opportunities with partners,” the release said.
Additionally, Leite is GoodRx’s first chief people officer, bringing decades of experience in global human resources and talent management.
GoodRx also announced the hire of Scott Paul as senior vice president of health and consumer innovation, who previously worked at MedImpact and Apex Affinity. The announcement also stated that Andrew Slutsky “will transition to a new role at the company, driving new initiatives as Senior Vice President of Strategy & Marketing Innovation.”
GoodRx, which states in marketing materials that it has helped consumers save more than $35 billion since 2011, recently topped the PYMNTS Provider Ranking of Prescription Apps.
See also: GoodRX Pays $150M for Health Platform vitaCare
On March 1, GoodRx announced it was acquiring vitaCare Prescription Services from TherapeuticsMD for $150 million. GoodRx also said it will pay an additional $7 million, contingent upon vitaCare’s financial performance through next year.
GoodRx Holdings, Inc. started calendar 2022 trading on the Nasdaq market at $32.45 a share. As of 3:30 p.m. Eastern Daylight Time on May 9, shares were trading at $10.76 a share, a decline of 67%.
We’re always on the lookout for opportunities to partner with innovators and disruptors.
Learn More